Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gut metagenome

ABSTRACT: Murine and Humanized intestinal microbiome in alcoholic liver disease Targeted loci

PROVIDER: PRJNA525701 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8703050_1.fastq.gz	Fastqsanger.gz
	SRR8703050_2.fastq.gz	Fastqsanger.gz
	SRR8703060_1.fastq.gz	Fastqsanger.gz
	SRR8703060_2.fastq.gz	Fastqsanger.gz
	SRR8703580_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1140

Similar Datasets

human gut mycobiome

Project description:Human intestinal mycobiome in alcoholic liver disease Targeted loci

| PRJNA517994 | ENA

human gut metagenome

Project description:Human gut mycobiome in alcoholic liver disease Targeted loci

| PRJNA317653 | ENA

human gut mycobiome

Project description:Human intestinal mycobiome in nonalcoholic fatty liver disease Targeted loci

| PRJNA698272 | ENA

Opisthorchis viverrini infection exacerbates kidney disease through gut dysbiosis and alteration of host proteome in nonalcoholic steatohepatitis hamsters

Project description:Non–alcoholic fatty liver disease (NAFLD) is high prevalent in worldwide and associated with chronic kidney disease (CKD). Infection with Opisthorchis viverrini (Ov) infection and consumption of high fat and high fructose (HFF) exacerbates NAFLD to nonalcoholic steatohepatitis in hamsters. Here, we aimed to investigate the effect a combination of HFF diet and Ov infection on kidney pathology via alteration of gut microbiome and proteome in hamster.

2024-09-12 | PXD045309 | JPOST Repository

mouse gut microbiome

Project description:Murine intestinal microbiome to explore the role of gp130 signalling Targeted loci

| PRJNA705611 | ENA

Effects of HIV infection and opioids on gut microbiota

Project description:Opioid use is associated with worse outcome in HIV-infected patients. The exacerbated disease progression by opioids is mainly driven by increased epithelial damage and less regenerative response. The present study investigates how opioids potentiate HIV disease progression by impairing intestinal epithelial self-repair. Abnormal intestinal morphology and reduced epithelial proliferation were observed in HIV-infected humanized mice, which were exposed to opioids. For this study, we had 4 groups of BLT humanized mice- (A) Untreated, (B) Morphine treated, (C) HIV infected and (D) HIV infected + Morphine treated. HIV infection was done for 4 weeks and Morphine treatment was done for 7 days. Morphine treatment was done via subcutaneous implantation of slow-release morphine pellet in individual mouse in the appropriate groups. In other groups, a matching Placebo pellet was implanted.

2020-01-11 | E-MTAB-7883 | biostudies-arrayexpress

mouse gut metagenome

Project description:Intestinal farnesoid X receptor signaling promotes non-alcoholic fatty liver disease

| PRJNA268203 | ENA

human and murine gut microbiome

Project description:human and murine gut microbiome Targeted loci

| PRJNA635258 | ENA

human and murine gut microbiome

Project description:human and murine gut microbiome Targeted loci

| PRJNA635260 | ENA

Manipulation of the gut microbiome as a strategy to treat the osteoarthritis of obesity

Project description:Obesity is a risk factor for Osteoarthritis (OA), the greatest cause of disability in the US. The impact of obesity on OA is driven by systemic inflammation, now understood to be caused by an altered gut microbiome. Oligofructose, a non-digestible prebiotic fiber, can correct the obese gut microbiome, suggesting a novel approach to treat the OA of obesity. Here we report that in the obese murine gut, beneficial Bifidobacteria are lost while key proinflammatory species gain in abundance. A downstream systemic inflammatory signature culminates with accelerated knee OA. Oligofructose supplementation corrects the obese gut microbiome in part by supporting key commensal microflora, particularly Bifidobacterium pseudolongum. This leads to reduced inflammation in the colon, circulation and knee, and protection from OA. This novel recognition of a gut microbiome-OA connection sets the stage for discovery of new OA therapeutics targeting specific microbes inhabiting the intestinal space to inhibit disease pathology.

2018-06-22 | GSE98287 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data